Last reviewed · How we verify
NCT05094583: SMOKEFREE
The SmokeFree App Smoking Cessation Study
trial testing Use of SmokeFree app in Smoking Cessation in 50 participants. Suspended.
4 December 2021
Quick facts
| Lead sponsor | Chelsea and Westminster NHS Foundation Trust |
|---|---|
| Status | Suspended |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 4 December 2019 |
| Primary completion | 4 December 2021 |
| Estimated completion | 4 December 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Use of SmokeFree app
Conditions studied
- Smoking Cessation — all drugs for Smoking Cessation →
- Smoking — all drugs for Smoking →
- Smoking Reduction — all drugs for Smoking Reduction →
- Smoking Habit — all drugs for Smoking Habit →
Sponsor
Chelsea and Westminster NHS Foundation Trust
Who can join
18 and older, any sex, with Smoking Cessation or Smoking. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
SmokeFree is a theory-driven and evidence-based stop smoking mobile application. Based on NICE guidance and best practice for smoking cessation, the application employs over 30 behaviour change techniques used in NHS Stop Smoking Services. It has been downloaded over 4 million times and has an average user rating of 4.7 out of 5, from over 120,000 ratings. Whilst user feedback has been highly positive, there is a need for further objective studies to demonstrate its efficacy. This is a prospective, observational, two arm feasibility study, which aims to evaluate the efficacy, attrition rate and user experience of the SmokeFree App. Inpatients in the Acute Medical Unit and ambulatory emergency care unit at Chelsea and Westminster Hospital who are current smokers will be offered to participate in the study, in addition to all other smoking cessation interventions, which will also be offered to them. Care will be taken to ensure that all available options of smoking cessation support are offered in addition to the SmokeFree application. Subjects agreeing to participate will be given access to the application for a period of 12 weeks, with a target quit date no later than week 8 of use of the application. At the end of 12 weeks they will be offered a follow up appointment in a purposely designed clinic, where their CO level will be measured, as well as being invited to complete feedback questionnaires on their experience. The primary end point of the study will be the quit rate for a period of minimum of 4 weeks by the completion of the 12 week trial. This will be confirmed with exhaled carbon monoxide testing. Secondary endpoints include user experience, engagement with the mobile application and attrition rate.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05094583
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Smoking Cessation
Currently open trials in the same condition.
- NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
- NCT07224087 — Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients · Phase 1 · recruiting
- NCT07331519 — Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer · NA · recruiting
- NCT07210567 — Mindfulness-based Ecological Momentary Intervention for Smoking Cessation Among Cancer Survivors · NA · recruiting
- NCT07129590 — Trauma-Informed Care for Smoking Cessation for Pregnancy · NA · recruiting
Other Chelsea and Westminster NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07124390 — Electroacupuncture as a Treatment for Refractory Overactive Bladder · NA · not yet recruiting
- NCT07202221 — Spoken Animation for Labour Epidural · NA · not yet recruiting
- NCT06775769 — Endometrioma Sclerotherapy and Ovarian Preservation · NA · recruiting
- NCT05289986 — The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients · Phase 4 · terminated
- NCT06118632 — Physiological and Environmental Data in a Remote Setting to Predict Exacerbation Events in Patients With Chronic Obstruc · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05094583 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chelsea and Westminster NHS Foundation Trust
- Last refreshed: 26 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05094583.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing